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Abstract
Background: Late effects after radiotherapy in childhood and adolescence have mainly been
characterized retrospectively with small patient numbers. However, these analyses are limited due
to little information regarding organ dose levels in many cases. To overcome this limitation, the
German Group of Paediatric Radiation Oncology (APRO) established the „Registry for the
evaluation of late side effects after radiation in childhood and adolescence” (RiSK). The study
protocol and the documentation forms are given in this publication.
Methods/Design:  Radiation parameters including detailed organ doses as well as toxicity
evaluations are collected prospectively from centres all over Germany. Standardized
documentation forms are used. These forms are given in an English and German version as
additional files to this publication. Documentation is planned for all children who receive
radiotherapy in one of the therapy trials of the "German Society of Paediatric Oncology and
Haematology (GPOH)". The study started in a pilot phase in June 2001 in few centres. Since 2004
documentation has been performed all over Germany and is still on-going.
Discussion: To our knowledge, "RiSK" is the only multi-centre study that evaluates radiation
associated side effects prospectively with detailed information about organ dose levels. With
ongoing recruitment and prolongation of follow-up powerful data will be obtained in a few years.
A broad use and international cooperation are welcome.
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Background
Radiotherapy is of fundamental importance in paediatric
oncology. Individual decisions for the use of ionizing
radiation always have to consider the potential benefit
and possible side effects. Whereas the benefit is no matter
of major discussions, the risk for potential side effects like
secondary malignancies and non-cancer health effects
cannot be quantified based on sufficient data. Especially,
there is a lack of information regarding dose-effect rela-
tionships of ionizing radiation. This is of special impor-
tance when ionizing radiation is used in childhood and
adolescence due to potential higher vulnerability of grow-
ing tissue and longer expected life span [1-3]. For radio-
therapy, late effects after treatment in childhood and
adolescence have mainly been characterized retrospec-
tively with small patient numbers [4-7]. Many of these
analyses are limited due to little information about organ
dose levels and older radiation techniques in some cases.
Recently, the characterization of late effects after cancer
therapy in childhood including chemotherapy, surgery
and radiation has been of rising interest [8,9]. Several
study groups in a variety of countries have developed
strategies to characterize different aspects of late effects. In
Germany, several study groups like the "Late Effects Sur-
veillance System" (LESS) [10,11] or the working group
"Quality of life" [12] have been established. The largest
examination has been performed in the United States of
America: The "Childhood Cancer Survivor Study" has
been established to characterize retrospectively the health
status of 5-year-survivors of childhood cancer. In these
studies, more than 12,000 patients were evaluated by
questionnaires regarding their health status [8]. For radia-
tion exposure, this study cannot give very detailed infor-
mation about organ-dose level associated late side effects
due to quite insufficient data regarding radiation organ
dose levels. So this approach turned out to be not suffi-
cient in view of answering open questions regarding the
risks of radiotherapy in childhood and adolescence.
Methods/Design
To overcome the described lack of information and to
receive detailed data regarding the risk of radiotherapy in
childhood and adolescence, the German Group of Paedi-
atric Radiation Oncology (APRO), a working group of the
"German Society of Radiation Oncology" (DEGRO) and
the "German Society of Paediatric Oncology and Haema-
tology" (GPOH) established the „Registry for the evalua-
tion of late side effects after radiation in childhood and
adolescence” (RiSK) [1-3]. The aim of this prospective
multi-centre registry study is to evaluate radiation dose-
effect relationships in organs and part of organs with spe-
cial regard to late side effects. Documentation is planned
for all children who receive radiotherapy in one of the
therapy optimizing study trials of the GPOH. The docu-
mentation of radiotherapy is performed through local
radiotherapists; the documentation forms are reviewed
and collected in the study centre in Münster. In addition,
the names of children who receive radiotherapy are col-
lected from the therapy study centres of the GPOH study
trials. The documentation forms of these patients are
asked for in the departments of radiotherapy if no docu-
mentation has been performed. Parents' declarations of
consent for data transfer have been integrated into most of
the study protocols of the GPOH that are relevant in view
of radiotherapy. Therefore additional declarations of con-
sent are not necessary in Germany. The first toxicity eval-
uation, i.e. the documentation of acute toxicities, is
scheduled at 6–8 weeks after the end of radiotherapy.
Later on, toxicity evaluations have to be performed once a
year. The evaluation of toxicities is performed either by
the radiation oncologists or, due to problems in some
departments, by the treating paediatric oncologists.
In a first step of RiSK, its structure was established and the
documentation forms were developed. They include the
evaluation of the treatment period, the fractionation
schedule, the target volume(s) as well as the radiation
techniques and doses including detailed information
about organ dose levels. A study group (see Acknowledge-
ments) of the APRO defined doses for each organ that
should lead to documentation if these doses are reached.
Beside the documentation of the maximum doses for
some organs, the dose-volume histograms have to be
characterized for the lungs, the heart, the liver and the kid-
neys. In case of the thyroid gland and the testes, dose
measurements have to be performed. Surgery and chemo-
therapy are evaluated as well. Toxicity documentation is
performed according to EORTC/RTOG criteria [13],
adapted to paediatric values. The toxicity is characterized
in 5 degrees (0 = no side effect, 4 = severe side effect) for
each organ. There is no need for additional examinations
in follow-up because the toxicity evaluations refer to the
standard follow-up examinations. The study flow chart is
given in Table 1. The documentation forms are available
in the internet [14] and given as additional files to this
publication in an English (see additional file 1) and a Ger-
man (see additional file 2) version. The documentation
for RiSK started in July 2001 with a pilot phase in few
study centres. During this period, the documentation
forms have been re-evaluated and adapted to the practical
need. Since February 2004, the documentation has been
performed all over Germany in a multi-centre way. The
feasibility of "RiSK" has already been shown [1] and first
results have recently been published [2,3].
Discussion
Sufficient data regarding radiation associated late seque-
lae after radiotherapy in childhood and adolescence with
special emphasis on organ dose-volume effects do not
exist. Due to the lack of detailed organ dose evaluation inRadiation Oncology 2008, 3:10 http://www.ro-journal.com/content/3/1/10
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the pre-3-D-treatment planning era, retrospective analyses
can only be performed with very uncertain estimations of
the radiation doses at special organs. To our knowledge,
"RiSK" is the only multi-centre study that evaluates radia-
tion associated side effects prospectively with detailed
information about organ dose levels. With ongoing
recruitment and prolongation of follow-up powerful data
will be obtained in a few years. The described study proto-
col and the documentation forms are open for the use by
other study groups. To further increase the number of
patients in order to obtain faster results, an international
cooperation with other study groups evaluating radiation
associated side effects after radiotherapy in childhood and
adolescence is welcome.
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Table 1: Study flow chart.
Timepoint Documentation Special needs
Treatment planning and radiotherapy Basic data (see documentation form part 1)
Organ doses (see documentation form part 2) 1. Dose-volume-histogram for lungs, heard, 
liver and kidneys, if in radiation field. Therefore 
CT-based treatment planning is mandatory if 
irradiation is performed to the thorax or 
abdomen.
2. Dosimetry of the thyroid gland if irradiation 
in head/neck area or mediastinum
3. Dosimetry of the testes if irradiation is 
performed to the abdomen or to the upper 
part of the lower extremity
6–8 weeks after end of radiotherapy
Follow-up examination
Documentation of maximal side effects that 
occured during or few weeks after 
radiotherapy according RTOG/EORTC criteria 
(see documentation form)
Only clinical examination
1 year after end of radiotherapy: follow-up 
examination
Evaluation of late sequelae according to RTOG/
EORTC criteria (see documentation form)
Only clinical examination, blood values to be 
asked from paediatricians
2nd-10th (if feasible) year after radiotherapy 
follow-up examination 1×/year
Evaluation of late sequelae according to RTOG/
EORTC criteria (see documentation form)
Only clinical examination, blood values to be 
asked from paediatricians
The documentation forms have to be sent to the RiSK study trial center in Münster: RiSK-Study trial centre, Department of Radiotherapy, 
University Hospital of Münster, Albert-Schweitzer-Str. 33, D-48129 Münster, Germany, Phone: +49-251-83-47384, Fax: +49-251-83-47355, E-Mail: 
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